Cannabinoid receptor type 1 immunoreactivity and disease severity in human epithelial ovarian tumors

Em, Messalli; Grauso, Flavio; Luise, R; Angelini, Anna; Rossiello, Raffaele

doi:10.1016/j.ajog.2014.04.004

Cited by 47 publications

(43 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Thus, CB1 receptor was found to be upregulated in Hodgkin lymphoma cells (Benz et al, 2013) and in chemically induced cellular hepatocarcinoma (Mukhopadhyay et al, 2015). CB1 receptors levels are also increased and correlate with disease severity in human epithelial ovarian tumors (Messalli et al, 2014) and have been proposed to be a factor of bad prognosis following surgery in stage IV colorectal cancer (Jung et al, 2013) Regarding CB2 receptor, a correlation between its expression, histologic grade and prognosis has been demonstrated in breast cancer (Caffarel et al, 2006) and glioma (Sanchez et al, 2001). In this latter tumor type a combined up-regulation of CB1 and CB2 receptors has been proposed to occur together with a decrease on the levels of the enzymes involved in endocannabinoid degradation compared healthy controls (Wu et al, 2012).…”

Section: -Endocannabinoid System: Role In Tumor Generation and Progrmentioning

confidence: 94%

The use of cannabinoids as anticancer agents

Velasco

Hernández-Tiedra

Dávila

et al. 2016

Progress in Neuro-Psychopharmacology and Biological Psychiatry

137

101

View full text Add to dashboard Cite

It is well-established that cannabinoids exert palliative effects on some cancer-associated symptoms. In addition evidences obtained during the last fifteen years support that these compounds can reduce tumor growth in animal models of cancer. Cannabinoids have been shown to activate an ER-stress related pathway that leads to the stimulation of autophagy-mediated cancer cell death. In addition, cannabinoids inhibit tumor angiogenesis and decrease cancer cell migration. The mechanisms of resistance to cannabinoid anticancer action as well as the possible strategies to develop cannabinoid-based combinational therapies to fight cancer have also started to be explored. In this review we will summarize these observations (that have already helped to set the bases for the development of the first clinical studies to investigate the potential clinical benefit of using cannabinoids in anticancer therapies) and will discuss the possible future avenues of research in this area.

show abstract

Section: -Endocannabinoid System: Role In Tumor Generation and Progrmentioning

confidence: 94%

The use of cannabinoids as anticancer agents

Velasco

Hernández-Tiedra

Dávila

et al. 2016

Progress in Neuro-Psychopharmacology and Biological Psychiatry

137

101

View full text Add to dashboard Cite

show abstract

“…These endpoints have not been associated with near‐signalling phenotypes, but one study to date has revealed that astrocytoma subclones signal through the pro‐survival Akt pathway in a manner dependent on high expression of CB 1 receptors (Cudaback et al, ), a finding that was replicated in prostate cancer tissue (Cipriano et al, ). Relatedly, an up‐regulation of CB 1 receptors has been reported in a variety of other cancers, including Hodgkin lymphoma (Benz et al, ), human epithelial ovarian tumours (Messalli et al, ) and stage four colorectal cancer (Jung et al, ) and has been shown to correlate with disease severity in the latter two cases. Thus, substantial conflicts remain in the literature and emphasize the complex interconnections between CB 1 receptor near signalling phenotypes and downstream endpoints such as cell fate.…”

Section: Discussionmentioning

confidence: 86%

Gα_s signalling of the CB₁ receptor and the influence of receptor number

Finlay

Cawston

Grimsey

et al. 2017

British J Pharmacology

118

View full text Add to dashboard Cite

CB receptor coupling to opposing G proteins is determined by both receptor and G protein expression levels, which underpins a mechanism for non-canonical signalling in a fashion consistent with Gα signalling. CB receptors mediate opposite consequences in endpoints such as tumour viability depending on expression levels; our results may help to explain such effects at the level of G protein coupling.

show abstract

“…These findings led to the suggestion that these are targets for new therapies for ovarian cancer . Recently studies also showed that CB 1 receptor levels are also increased and correlate with disease severity in human epithelial ovarian tumours and this has been proposed to be an important factor of bad prognosis following surgery in 24 stage IV colorectal cancer (Messalli et al, 2014;Jung et al, 2013). WIN-55,212-2 was shown to exert, via CBR dependent manner, a decrease in cell viability, G1 arrest in cell cycle progression, induction of apoptosis and down-regulation of the expression of PCNA and VEGF ).…”

Section: Cannabinoids and Reproductive System Cancermentioning

confidence: 99%

Cannabinoid pharmacology in cancer research: A new hope for cancer patients?

Javid

Phillips

Afshinjavid

et al. 2016

European Journal of Pharmacology

View full text Add to dashboard Cite

Cannabinoids have been used for many centuries to ease pain and in the past decade, the endocannabinoid system has been implicated in a number of pathophysiological conditions, such as mood and anxiety disorders, movement disorders such as Parkinson's and Huntington's disease, neuropathic pain, multiple sclerosis, spinal cord injury, atherosclerosis, myocardial infarction, stroke, hypertension, glaucoma, obesity, and osteoporosis. Several studies have demonstrated that cannabinoids also have anti-cancer activity and as cannabinoids are usually well tolerated and do not produce the typical toxic effects of conventional chemotherapies, there is considerable merit in the development of cannabinoids as potential anticancer therapies. Whilst the presence of psychoactive effects of cannabinoids could prevent any progress in this field, recent studies have shown the value of the non-psychoactive components of cannabinoids in activating apoptotic pathways, inducing anti-proliferative and anti-angiogenic effects. The aforementioned effects are suggested to be through pathways such as ERK, Akt, mitogen-activated protein kinase (MAPK) pathways, phosphoinositide 3-kinase (PI3K) pathways and hypoxia inducible factor 1 (HIF1), all of which are important contributors to the hallmarks of cancer. Many important questions still remain unanswered or are poorly addressed thus necessitating further research at basic pre-clinical and clinical levels. In this review, we address these issues with a view to identifying the key challenges that future research needs to address.

show abstract

Cannabinoid receptor type 1 immunoreactivity and disease severity in human epithelial ovarian tumors

Cited by 47 publications

References 32 publications

The use of cannabinoids as anticancer agents

The use of cannabinoids as anticancer agents

Gα_s signalling of the CB₁ receptor and the influence of receptor number

Cannabinoid pharmacology in cancer research: A new hope for cancer patients?

Contact Info

Product

Resources

About

Cannabinoid receptor type 1 immunoreactivity and disease severity in human epithelial ovarian tumors

Cited by 47 publications

References 32 publications

The use of cannabinoids as anticancer agents

The use of cannabinoids as anticancer agents

Gαs signalling of the CB1 receptor and the influence of receptor number

Cannabinoid pharmacology in cancer research: A new hope for cancer patients?

Contact Info

Product

Resources

About

Gα_s signalling of the CB₁ receptor and the influence of receptor number